NewsFlash Archive

more Events

  • 0%
    0 votes

    Helping Hand

    Monday, February 22, 2010

    A teenager who had to quit studying his favourite subject because of a rare disease has been given a helping hand by a local charityPortsmouth and Southsea Round Table presented Denni Edwards with a new camera and equipment to help him when he renews his photography studiesDenni, from Derby Road

    read more>>

  • 0%
    0 votes

    Rare Courage

    Monday, February 22, 2010

    It's every parent's worst nightmare: a child suffering in the grips of a disease that has no nameWhere do they go and what do they do? Three parents who have faced this issue tell their story to Juliana KerrAlthough the issues they’re dealing with are very different, the introduction of a r

    read more>>

  • 0%
    0 votes

    Bill Gates Gives Sh5 Billion for Sleeping Sickness in Africa

    Monday, February 22, 2010

    Kampala -- The University of Glasgow has received a $3m (sh5.8b) grant from the Bill and Melinda Gates Foundation to further the treatment of sleeping sickness (human African trypanosomiasisThe money will go towards developing new models to test the ability of drugs to treat this fatal disease in

    read more>>

  • 0%
    0 votes

    UCR Researcher Identifies Mechanism Malaria Parasite Uses to Spread Among Red Blood Cells

    Monday, February 22, 2010

    RIVERSIDE, Calif. -- Malaria remains one of the most deadly infectious diseasesYet, how Plasmodium, the malaria parasite, regulates its infectious cycle has remained an enigma despite decades of rigorous researchBut now a team led by a cell biologist at the University of California, Riverside has

    read more>>

  • 0%
    0 votes

    Exercise Helps Protect Brain of Multiple Sclerosis Patients

    Monday, February 22, 2010

    COLUMBUS, Ohio -- Highly fit multiple sclerosis patients perform significantly better on tests of cognitive function than similar less-fit patients, a new study showsIn addition, MRI scans of the patients showed that the fitter MS patients showed less damage in parts of the brain that show deterio

    read more>>

  • 0%
    0 votes

    New Endoscopic Treatment May Spare Barrett's Esophagus Patients From Surgery

    Monday, February 22, 2010

    Early tumor formation in Barrett's esophagus (BE) can be effectively and safely treated with radiofrequency ablation (RFA), in combination with prior endoscopic removal of visible lesions, according to a new study in Clinical Gastroenterology and Hepatology, the official journal of the American "B

    read more>>

  • 0%
    0 votes

    United Therapeutics Corporation Withdraws European Marketing Authorization Application for Tyvaso for the Treatment of Pulmonary Arterial Hypertension

    Monday, February 22, 2010

    SILVER SPRING -- United Therapeutics Corporation (Nasdaq: UTHR) announced today that it has withdrawn its Marketing Authorization Application (MAA) for Tyvaso (treprostinil sodium) 0.6 mg/ml nebuliser solution for the treatment of pulmonary arterial hypertension (PAH) in the European UnionUnited T

    read more>>

  • 0%
    0 votes

    Novartis Oral Multiple Sclerosis Development Compound Gilenia(R) (FTY720) Granted US Priority Review Status

    Monday, February 22, 2010

    Basel -- Gilenia®* (FTY720, fingolimod) has been granted priority review status by the US Food and Drug Administration (FDA), which accepted the regulatory submission made in December 2009 for this medicineOnce-daily Gilenia (0.5 mg) has the potential to become the first approved oral therapy

    read more>>

  • 0%
    0 votes

    NHLBI, CDC Launch Surveillance and Research Program for Inherited Blood Diseases

    Monday, February 22, 2010

    Medical researchers are developing a new surveillance system to determine the number of patients diagnosed with a family of inherited blood disorders known as hemoglobinopathies, including sickle cell disease, thalassemias, and hemoglobin E diseaseThe National Heart, Lung, and Blood Institute (NHL

    read more>>

  • 0%
    0 votes

    GlaxoSmithKline and XenoPort Receive FDA Complete Response Letter for Horizant(TM)

    Friday, February 19, 2010

    London, UK, Research Triangle Park, NC & Santa Clara, CA -- GlaxoSmithKline (NYSE: GSK) and XenoPort, Inc. (Nasdaq: XNPT) Wednesday received a Complete Response letter from the U.S. Food and Drug Administration (FDA) regarding the New Drug Application (NDA) for Horizant™(gabapentin A Co

    read more>>